Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells.

The median BCR::ABL gene expression was downregulated in pioglitazone group compared to the historical group significantly at the 3rd (3.65% vs 7%; P = 0.046) and the 6th month(0.75% vs 0.2%; P = 0.049), though it was marginally insignificant at 12th month(0.25% vs0.1%: P = 0.056).However, starting from 18th month the difference between both groups was statistically insignificant (0.02% vs 0.06%; P = 0.317).

also in 511 other papers

Additionally, a greater proportion of patients in the study group achieved a 12-month major molecular response (MMR) (65.3%) compared to 50% in the historical control group, although this difference did not reach statistical significance [Table 4 ].

also in 111,027 other papers